title: A model of 'epileptic tolerance' for investigating neuroprotection, epileptic susceptibility and gene expression-related plastic changes.
abstract: Previous insult, for example, sustained epileptic seizures, confers a substantial temporary protection against the cellular damage induced by subsequent epileptic challenge. Here we describe a useful model of this so-called 'epileptic tolerance'. Expression of a status epilepticus was triggered by infusing the excitotoxic agent, kainate, into the right hippocampus of adult rats. An appropriate dose of kainate was used to cause brain damage in the homolateral, but not contralateral, hippocampus. At various times following this preconditioning insult, kainate was then re-administered into the lateral ventricle and neuroprotection was observed in the contralateral side between 1 and 15 days later. This model can be used to investigate the mechanisms of this endogenous neuroprotection. It is also particularly suitable for studying the epileptic susceptibility, as reflected by the modifications of the after-discharge threshold, as well as any changes in gene expression induced associated with the preconditioning episode.
authors.affiliation: Laboratoire d'Epileptologie Expérimentale et Clinique-EA 2967, Université Victor Segalen Bordeaux2, Bordeaux, France.
authors.forename: Carole
authors.initials: C
authors.lastname: Leré
authors.forename: Bouchaib
authors.initials: B
authors.lastname: El Bahh
authors.forename: Gildas
authors.initials: G
authors.lastname: Le Gal La Salle
authors.forename: Alain
authors.initials: A
authors.lastname: Rougier
mesh_terms: D000818:Animals; D016923:Cell Death / Q000187:drug effects / Q000502:physiology; D002470:Cell Survival / Q000502:physiology*; D004195:Disease Models, Animal; D004827:Epilepsy / Q000473:pathology / Q000503:physiopathology*; D018690:Excitatory Amino Acid Agonists / Q000494:pharmacology; D005786:Gene Expression Regulation / Q000502:physiology; D006624:Hippocampus / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D019194:Ischemic Preconditioning / Q000379:methods*; D007608:Kainic Acid / Q000494:pharmacology; D008297:Male; D009473:Neuronal Plasticity / Q000502:physiology; D009478:Neuropeptide Y / Q000378:metabolism; D017966:Pyramidal Cells / Q000187:drug effects / Q000473:pathology; D051381:Rats; D017208:Rats, Wistar; D013226:Status Epilepticus / Q000139:chemically induced* / Q000473:pathology / Q000503:physiopathology
chemical_list: D018690:Excitatory Amino Acid Agonists; D009478:Neuropeptide Y; D007608:Kainic Acid